CO2017004543A2 - Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural - Google Patents
Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma naturalInfo
- Publication number
- CO2017004543A2 CO2017004543A2 CONC2017/0004543A CO2017004543A CO2017004543A2 CO 2017004543 A2 CO2017004543 A2 CO 2017004543A2 CO 2017004543 A CO2017004543 A CO 2017004543A CO 2017004543 A2 CO2017004543 A2 CO 2017004543A2
- Authority
- CO
- Colombia
- Prior art keywords
- mhc
- peptide
- peptide ligand
- preparation
- intended
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
La presente invención se refiere a un método para la cuantificación absoluta de péptidos cancerosos restringidos a HLA que son procesados de forma natural, es decir, para la determinación del número de copias del péptido o péptidos que son presentados por cada célula, en donde el método comprende las etapas de a) preparación de las células que presentan, como mínimo, dicho ligando peptídico del MHC a partir de una muestra biológica que contenga células, b) determinación del número de células en la citada preparación resultante de la etapa a), c) adición de una cantidad conocida de al menos dicho ligando peptídico-MHC y/o complejo de ligando peptídico-MHC que se pretende cuantificar resultante de la citada preparación de la etapa a), d) aislamiento de al menos un ligando peptídico del MHC resultante de la citada preparación de la etapa c), e) adición de una cantidad conocida de al menos un ligando peptídico del MHC que se pretende cuantificar al citado eluato de péptido, f) ejecución de un análisis por espectrometría de masas con al menos dicho ligando peptídico del MHC, y g) cuantificación de, al menos, el citado ligando peptídico del MHC basada en la comparación de las señales obtenidas en la etapa f). La presente invención no solo está destinada al desarrollo de terapias con anticuerpos o de vacunas peptídicas, sino que es también sumamente valiosa para la inmunovigilancia definida con criterios moleculares, y resulta útil en los procesos de identificación de nuevos antígenos peptídicos para estrategias inmunoterapéuticas, tales como vacunas, terapias con anticuerpos o transferencia adoptiva de linfocitos T contra el cáncer, enfermedades infecciosas y/o autoinmunitarias.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097994P | 2014-12-30 | 2014-12-30 | |
| GBGB1423361.3A GB201423361D0 (en) | 2014-12-30 | 2014-12-30 | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| PCT/EP2015/079873 WO2016107740A1 (en) | 2014-12-30 | 2015-12-15 | Method for the absolute quantification of naturally processed hla-restricted cancer peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017004543A2 true CO2017004543A2 (es) | 2017-09-29 |
Family
ID=52471641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0004543A CO2017004543A2 (es) | 2014-12-30 | 2017-05-05 | Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10545154B2 (es) |
| EP (1) | EP3241026B1 (es) |
| JP (1) | JP6735741B2 (es) |
| KR (1) | KR102336968B1 (es) |
| CN (1) | CN107003322B (es) |
| AU (1) | AU2015373584B2 (es) |
| BR (1) | BR112017008212B1 (es) |
| CA (1) | CA2972306C (es) |
| CL (1) | CL2017001071A1 (es) |
| CO (1) | CO2017004543A2 (es) |
| CR (1) | CR20170297A (es) |
| CY (1) | CY1124223T1 (es) |
| DK (1) | DK3241026T3 (es) |
| EA (1) | EA036328B1 (es) |
| ES (1) | ES2871035T3 (es) |
| GB (1) | GB201423361D0 (es) |
| HR (1) | HRP20210811T1 (es) |
| HU (1) | HUE054455T2 (es) |
| IL (1) | IL250982B (es) |
| LT (1) | LT3241026T (es) |
| MA (2) | MA40137B1 (es) |
| MD (1) | MD3241026T2 (es) |
| MX (1) | MX2017008722A (es) |
| MY (1) | MY190199A (es) |
| PE (1) | PE20171136A1 (es) |
| PH (1) | PH12017500483A1 (es) |
| PL (1) | PL3241026T3 (es) |
| PT (1) | PT3241026T (es) |
| RS (1) | RS61914B1 (es) |
| SG (2) | SG11201703841VA (es) |
| SI (1) | SI3241026T1 (es) |
| TW (1) | TWI632370B (es) |
| UA (1) | UA122774C2 (es) |
| WO (1) | WO2016107740A1 (es) |
| ZA (1) | ZA201701646B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| TWI755158B (zh) * | 2015-03-17 | 2022-02-11 | 德商英麥提克生物技術股份有限公司 | 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合 |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| AU2018298884A1 (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| JP7470640B2 (ja) * | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| KR20200027858A (ko) * | 2018-09-05 | 2020-03-13 | 에스케이하이닉스 주식회사 | 메모리 컨트롤러 및 이를 포함하는 메모리 시스템 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210041454A1 (en) | 2019-08-09 | 2021-02-11 | Immatics US, Inc. | Methods for peptide mass spectrometry fragmentation prediction |
| US20210048442A1 (en) | 2019-08-13 | 2021-02-18 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:mhc binding polypeptides |
| MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| JP2023527293A (ja) | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Ｃｄ８多肽、組合物及其使用方法 |
| AU2022269828A1 (en) | 2021-05-05 | 2023-11-23 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230057987A1 (en) | 2021-07-27 | 2023-02-23 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding ct45 |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230190805A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of identifying metastatic lesions in a patient and treating thereof |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4290003B2 (ja) | 2001-09-14 | 2009-07-01 | エレクトロフォレティクス リミテッド | 質量標識体 |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| US6644103B1 (en) | 2002-10-24 | 2003-11-11 | Simmonds Precision Products, Inc. | Method and apparatus for detecting a dry/wet state of a thermistor bead |
| WO2004042401A1 (ja) * | 2002-11-08 | 2004-05-21 | Hiroshi Takahashi | 癌細胞の検査方法及びそのための試薬 |
| JP2007519910A (ja) | 2004-01-28 | 2007-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 腫瘍関連ペプチドの同定および定量方法 |
| JP2008043332A (ja) * | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
| ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| WO2012140429A2 (en) | 2011-04-15 | 2012-10-18 | Micromass Uk Limited | Method and apparatus for the analysis of biological samples |
| WO2012178030A2 (en) | 2011-06-24 | 2012-12-27 | Applied Isotope Technologies, Inc. | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening |
| US10077171B2 (en) * | 2012-10-17 | 2018-09-18 | Grant C. Chustz | Safety barrier for vehicles and cranes |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| IL274505B2 (en) * | 2017-11-06 | 2024-04-01 | Immatics Biotechnologies Gmbh | Transgenic T-cell receptors and immunotherapy using them |
-
2014
- 2014-12-30 GB GBGB1423361.3A patent/GB201423361D0/en not_active Ceased
-
2015
- 2015-12-15 PT PT158229245T patent/PT3241026T/pt unknown
- 2015-12-15 HU HUE15822924A patent/HUE054455T2/hu unknown
- 2015-12-15 CA CA2972306A patent/CA2972306C/en active Active
- 2015-12-15 WO PCT/EP2015/079873 patent/WO2016107740A1/en active Application Filing
- 2015-12-15 MD MDE20170252T patent/MD3241026T2/ro unknown
- 2015-12-15 MY MYPI2017700825A patent/MY190199A/en unknown
- 2015-12-15 LT LTEP15822924.5T patent/LT3241026T/lt unknown
- 2015-12-15 SI SI201531612T patent/SI3241026T1/sl unknown
- 2015-12-15 PL PL15822924T patent/PL3241026T3/pl unknown
- 2015-12-15 BR BR112017008212-8A patent/BR112017008212B1/pt active IP Right Grant
- 2015-12-15 EA EA201791148A patent/EA036328B1/ru unknown
- 2015-12-15 SG SG11201703841VA patent/SG11201703841VA/en unknown
- 2015-12-15 RS RS20210672A patent/RS61914B1/sr unknown
- 2015-12-15 MA MA40137A patent/MA40137B1/fr unknown
- 2015-12-15 ES ES15822924T patent/ES2871035T3/es active Active
- 2015-12-15 DK DK15822924.5T patent/DK3241026T3/da active
- 2015-12-15 MA MA41287A patent/MA41287B1/fr unknown
- 2015-12-15 PE PE2017000941A patent/PE20171136A1/es unknown
- 2015-12-15 EP EP15822924.5A patent/EP3241026B1/en active Active
- 2015-12-15 US US14/969,423 patent/US10545154B2/en active Active
- 2015-12-15 CN CN201580063711.6A patent/CN107003322B/zh active Active
- 2015-12-15 CR CR20170297A patent/CR20170297A/es unknown
- 2015-12-15 MX MX2017008722A patent/MX2017008722A/es unknown
- 2015-12-15 KR KR1020177017911A patent/KR102336968B1/ko active IP Right Grant
- 2015-12-15 AU AU2015373584A patent/AU2015373584B2/en active Active
- 2015-12-15 TW TW104142137A patent/TWI632370B/zh active
- 2015-12-15 UA UAA201701977A patent/UA122774C2/uk unknown
- 2015-12-15 SG SG10201913988XA patent/SG10201913988XA/en unknown
- 2015-12-15 JP JP2017521534A patent/JP6735741B2/ja active Active
-
2017
- 2017-03-07 IL IL250982A patent/IL250982B/en active IP Right Grant
- 2017-03-07 ZA ZA2017/01646A patent/ZA201701646B/en unknown
- 2017-03-14 PH PH12017500483A patent/PH12017500483A1/en unknown
- 2017-04-28 CL CL2017001071A patent/CL2017001071A1/es unknown
- 2017-05-05 CO CONC2017/0004543A patent/CO2017004543A2/es unknown
-
2019
- 2019-11-15 US US16/685,765 patent/US11988669B2/en active Active
-
2021
- 2021-05-19 HR HRP20210811TT patent/HRP20210811T1/hr unknown
- 2021-06-10 CY CY20211100514T patent/CY1124223T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004543A2 (es) | Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural | |
| AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
| CO2017013710A2 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t. | |
| CO2020001029A2 (es) | Molécula de polipéptido con especificidad dual mejorada | |
| WO2014036562A3 (en) | Target peptides for immunotherapy and diagnostics | |
| BR112019008560A2 (pt) | célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação | |
| CR20170032A (es) | Moleculas biespecíficas de unión a antígeno activadoras de células t | |
| WO2017184590A8 (en) | Improved hla epitope prediction | |
| CY1121743T1 (el) | Μονοκλωνικα αντισωματα προς χρηση στη διαγνωση και θεραπεια απο καρκινους και αυτοανοση νοσο | |
| JP2018500004A5 (es) | ||
| CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
| AR093984A1 (es) | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano | |
| AR094896A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
| MX2016016904A (es) | Analisis de secuencias de acidos nucleicos. | |
| ES2672895T3 (es) | Generación de células T específicas de antígeno | |
| MX2017003625A (es) | Reactivos y metodos para identificar, enriquecer y/o expander celulas t especificas de antigeno. | |
| IN2014DN07531A (es) | ||
| EA201891459A1 (ru) | Новое поколение антигенспецифических tcr | |
| BR112017003472A2 (pt) | anticorpos, fragmento fab de anticorpo e método para o tratamento de uma doença inflamatória | |
| BR112016013845A2 (pt) | Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças | |
| AR114001A1 (es) | Anticuerpos que se unen a hla- a2 / wt1 | |
| BR112017002622A2 (pt) | métodos e sistemas para quantificação seletiva e detecção de alergênicos | |
| BR112017019236A2 (pt) | kit, e, método para detectar a presença de anticorpos de sífilis em uma amostra | |
| AR112228A1 (es) | Molécula de polipéptido con especificidad dual mejorada |